Interim report January-March 2011

Period January - March
· The Group's net sales for the period were SEK 134 (131) million. Adjusted for
the divested OTC products, sales were SEK 112 million for the previous year.
· EBITDA for the period amounted to SEK 31 (18) million. Adjusted for the
divested OTC products, EBITDA for the previous year was SEK 10 million.
· Operating profit totalled SEK 25 (11) million.
· Profit/loss after tax for the period was SEK 18 (-3) million.
· Earnings per share after tax, before and after dilution, for the period were
SEK 0.05 (-0.01).
Significant events during the period
· BioPhausia acquired renewed confidence as the main supplier of parallel-
imported pharmaceuticals to Apoteksgruppen.
Significant events after the period
· On 11 April Medivir AB submitted a public takeover bid for all shares and
listed warrants in BioPhausia.


[HUG#1516044]